BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33734039)

  • 21. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2
    Musoev A; Numonov S; You Z; Gao H
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based pharmacophore modeling, virtual screening and simulation studies for the identification of potent anticancerous phytochemical lead targeting cyclin-dependent kinase 2.
    Sharma M; Sharma N; Muddassir M; Rahman QI; Dwivedi UN; Akhtar S
    J Biomol Struct Dyn; 2022; 40(20):9815-9832. PubMed ID: 34151738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of potential Aurora-A kinase inhibitors by 3D QSAR pharmacophore modeling, virtual screening, docking, and MD simulation studies.
    Swamy P M G; Abbas N; Dhiwar PS; Singh E; Ghara A; Das A
    J Biomol Struct Dyn; 2023 Jan; 41(1):125-146. PubMed ID: 34809538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacophore model, docking, QSAR, and molecular dynamics simulation studies of substituted cyclic imides and herbal medicines as COX-2 inhibitors.
    Moussa N; Hassan A; Gharaghani S
    Heliyon; 2021 Apr; 7(4):e06605. PubMed ID: 33889764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insight parameter drug design for human β-tryptase inhibition integrated molecular docking, QSAR, molecular dynamics simulation, and pharmacophore modelling studies of α-keto-[1,2,4]-oxadiazoles.
    Yu CX; Tan JW; Rullah K; Imran S; Tham CL
    J Biomol Struct Dyn; 2023; 41(22):12978-12996. PubMed ID: 36709457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
    Shanmugam V; Muthukrishnan S
    J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of novel inhibitor of protein tyrosine phosphatases delta: structure-based pharmacophore modeling, virtual screening, flexible docking, molecular dynamics simulation, and post-molecular dynamics analysis.
    Ma YC; Yang B; Wang X; Zhou L; Li WY; Liu WS; Lu XH; Zheng ZH; Ma Y; Wang RL
    J Biomol Struct Dyn; 2020 Sep; 38(15):4432-4448. PubMed ID: 31625456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integration of ligand and structure-based pharmacophore screening for the identification of novel natural leads against Euchromatic histone lysine methyltransferase 2 (EHMT2/G9a).
    Jana A; Naga R; Saha S; Griñán-Ferré C; Banerjee DR
    J Biomol Struct Dyn; 2024 Apr; 42(7):3535-3562. PubMed ID: 37216299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing.
    Liu J; Zhu Y; He Y; Zhu H; Gao Y; Li Z; Zhu J; Sun X; Fang F; Wen H; Li W
    J Biomol Struct Dyn; 2020 Feb; 38(2):533-547. PubMed ID: 30938574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
    Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC
    Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Field and atom-based 3D-QSAR models of chromone (1-benzopyran-4-one) derivatives as MAO inhibitors.
    Saha M; Gupta S; Dhiman S; Asati V; Ali A; Ali A
    J Biomol Struct Dyn; 2023; 41(21):12171-12185. PubMed ID: 36650997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacophore modelling, docking and molecular dynamic simulation studies in the discovery of potential human renin inhibitors.
    Halimi M; Hajipasha A
    J Mol Graph Model; 2022 Nov; 116():108272. PubMed ID: 35932508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation.
    Raafat A; Mowafy S; Abouseri SM; Fouad MA; Farag NA
    Comput Biol Med; 2022 Jul; 146():105526. PubMed ID: 35487125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploration of Novel PDEδ Inhibitor Based on Pharmacophore and Molecular Docking against KRAS Mutant in Colorectal Cancer.
    Mouhcine M; Kadil Y; Rahmoune I; Filali H
    Curr Drug Discov Technol; 2023; 20(4):e160423215830. PubMed ID: 37066770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A virtual insight into mushroom secondary metabolites: 3D-QSAR, docking, pharmacophore-based analysis and molecular modeling to analyze their anti-breast cancer potential.
    Shafiq N; Shakoor B; Yaqoob N; Parveen S; Brogi S; Mohammad Salamatullah A; Rashid M; Bourhia M
    J Biomol Struct Dyn; 2024 Feb; ():1-22. PubMed ID: 38299565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer.
    Ajay Kumar TV; Athavan AAS; Loganathan C; Saravanan K; Kabilan S; Parthasarathy V
    Comput Biol Chem; 2018 Oct; 76():232-244. PubMed ID: 30077902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular modeling studies of novel naphthyridine and isoquinoline derivatives as CDK8 inhibitors.
    Li Q; Feng K; Liu J; Ren Y
    J Biomol Struct Dyn; 2021 Oct; 39(17):6355-6369. PubMed ID: 32723012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3D QSAR pharmacophore-based virtual screening for the identification of potential inhibitors of tyrosinase.
    Ghayas S; Ali Masood M; Parveen R; Aquib M; Farooq MA; Banerjee P; Sambhare S; Bavi R
    J Biomol Struct Dyn; 2020 Jul; 38(10):2916-2927. PubMed ID: 31334690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular modeling of pyrrolo-pyrimidine based analogs as potential FGFR1 inhibitors: a scientific approach for therapeutic drugs.
    Raza A; Chohan TA; Sarfraz M; Chohan TA; Imran Sajid M; Tiwari RK; Ansari SA; Alkahtani HM; Yasmeen Ansari S; Khurshid U; Saleem H
    J Biomol Struct Dyn; 2023; 41(23):14358-14371. PubMed ID: 36898855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In silico approaches to identify novel myeloid cell leukemia-1 (Mcl-1) inhibitors for treatment of cancer.
    Ren JX; Li CP; Zhou XL; Cao XS; Xie Y
    J Biomol Struct Dyn; 2018 Jul; 36(9):2424-2435. PubMed ID: 28714799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.